☆ 4.6 Article

Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis

BRITISH JOURNAL OF DERMATOLOGY (2014)

Journal

BRITISH JOURNAL OF DERMATOLOGY

Volume 170, Issue 2, Pages 415-424

Publisher

WILEY

DOI: 10.1111/bjd.12648

Keywords

-

Categories

Dermatology

Funding

University Medical Centre St Radboud Foundation
Pfizer

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Dermatology

Retrospective study of apremilast drug survival in psoriasis patients in a daily practice setting: A long-term experience

Cristina Galache-Osuna, Sebastian Reyes-Garcia, Esther Salgueiro, Javier Bordallo-Landa, Ana Lozano, Francisco Vazquez-Lopez, Jorge Santos-Juanes

Summary: This study aimed to evaluate the long-term survival of apremilast and its predictive factors when used to treat psoriasis. The results showed that apremilast may be a suitable and efficient alternative for the treatment of psoriasis patients in the PASI<10 group.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Article Dermatology

Blocking interleukin-17 in psoriasis: Real-world experience from the PsoPlus cohort

Lisa Schots, Rani Soenen, Brigitte Blanquart, Debby Thomas, Jo Lambert

Summary: This real-world study demonstrates that IL-17i are highly effective drugs for the treatment of psoriasis, with ixekizumab as the most effective biologic. Treatment modifications mainly occur in cases of inadequate response, primarily through switching medications and increasing doses, and least frequently in ixekizumab patients. Concentrations of the drug may rationalize clinical decision-making, but standardized algorithms are needed to validate its use.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Add to Collection

Article Dermatology

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study

L. M. Prens, K. Bouwman, P. Aarts, S. Arends, K. R. van Straalen, K. Dudink, B. Horvath, E. P. Prens

Summary: This study evaluated the drug survival of antitumour necrosis factor biologics for patients with hidradenitis suppurativa in daily practice. Survival rates for adalimumab and infliximab were similar at 12 months, mainly determined by ineffectiveness. Age, disease duration (adalimumab), and surgery (infliximab) were identified as predictors for longer drug survival.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain

Esteban Dauden, Glauber Pacelli Gomes de Lima, Susana Armesto, Enrique Herrera-Acosta, David Vidal, Eva Villarasa, Raquel Rivera, Pablo de la Cueva, Antonio Martorell, Ferran Ballesca, Isabel Belinchon, Gregorio Carretero, Lourdes Rodriguez, Alberto Romero-Mate, Josep Pujol-Montcusi, Laura Salgado, Antonio Sahuquillo-Torralba, Pablo Coto-Segura, Ofelia Baniandres, Rosa Feltes, Merce Alsina, Mar Llamas-Velasco

Summary: In this study, the drug survival rate of secukinumab for psoriasis patients was found to be within the range of real-world evidence studies from 6-18 months. Additionally, a relatively high long-term survival rate of 74.3% was observed at 24 months. Factors such as obesity and previous experience with biological therapies were associated with early treatment discontinuation, while psoriatic arthritis was associated with delayed discontinuation.

DERMATOLOGY AND THERAPY (2021)

Add to Collection

Article Dermatology

Comparison of Survival and Retention Rates between Infliximab and Adalimumab for Psoriasis: 10-year Experience at a Single Tertiary Center

N. Onsun, B. Gunes, G. Kaya, Guckan B. Isik, Yabaci A. Tak

Summary: This study evaluates the long-term survival rates of adalimumab and infliximab based on real-life clinical data, and finds that the efficacy of these two drugs decreases over time.

DERMATOLOGY (2023)

Add to Collection

Review Medicine, General & Internal

Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis

Ahmed I. Mourad, Robert Gniadecki

Summary: Drug survival studies in psoriasis assessed the comparative effectiveness of biologics like ustekinumab, adalimumab, etanercept, infliximab, secukinumab, and ixekizumab in real-world settings. Results showed ustekinumab had the longest persistence, with adalimumab outperforming etanercept and infliximab at 5 years. The estimated pooled 2- and 5-year drug survival rates can serve as a useful tool for patient communication and clinical decision-making.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Article Dermatology

Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience

Julian Distel, Simone Cazzaniga, S. Morteza Seyed Jafari, Vladimir Emelianov, Christoph Schlapbach, Nikhil Yawalkar, Kristine Heidemeyer

Summary: This study analyzed the characteristics, effectiveness, and drug survival of patients with psoriasis treated with apremilast in a real-world setting. The drug survival rate at 6, 12, and 24 months after therapy initiation was 69.5%, 34.7%, and 25.8% respectively. Most therapy discontinuations were due to loss of efficacy and adverse events. At 24 months, 35.9% of patients achieved PASI75 response, and 23.7% achieved PASI90 response.

DERMATOLOGY (2022)

Add to Collection

Article Rheumatology

Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020

Caitlin Norris-Grey, Geraldine Cambridge, Samantha Moore, Venkat Reddy, Maria Leandro

Summary: This study retrospectively reviewed the long-term persistence of rituximab in RA patients and identified factors associated with treatment discontinuation. The study found that many RA patients achieve good disease control with repeated cycles of rituximab treatment, but the main reason for discontinuation is treatment inefficacy. Seronegative patients and those who have previously failed other biologic DMARDs are at higher risk of drug discontinuation.

RHEUMATOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data

Tom Konikoff, Henit Yanai, Dror Libchik, Irit Avni-Biron, Yifat Snir, Hagar Banai, Yelena Broytman, Iris Dotan, Jacob E. Ollech

Summary: This study compared the drug sustainability (DS) of infliximab (IFX) and vedolizumab (VDZ), two main biologics used to treat moderate-to-severe ulcerative colitis (UC), in a real-world setting. The results showed that VDZ had a significantly longer DS compared to IFX in treatment-naive patients, even when adjusted for disease severity. However, there was no difference in DS between the two drugs in treatment-experienced patients.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Rheumatology

Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study

Irini Flouri, Panagiota Goutakoli, Argyro Repa, Antonios Bertsias, Nestor Avgoustidis, Anastasios Eskitzis, Sofia Pitsigavdaki, Eleni Kalogiannaki, Maria Terizaki, George Bertsias, Prodromos Sidiropoulos

Summary: This study characterized disease activity trajectories and compared long-term drug retention between rheumatoid arthritis (RA) and spondylarthritis (SpA) patients initiating tumor necrosis factor inhibitor (TNFi) treatment. The study found that discontinuation of TNFi treatment was independent of the diagnosis and was predicted by gender and obesity. Disease activity trajectories revealed heterogeneity in treatment responses and prognosis.

RHEUMATOLOGY INTERNATIONAL (2023)

Add to Collection

Review Immunology

Durability and long-term outcomes of biologic therapies in psoriasis

Lluis Rusinol, Elena Carmona-Rocha, Lluis Puig

Summary: Significant advances in psoriasis treatment have been achieved with the introduction of biologics, especially the newer ones targeted to IL-23/IL-17 pathways. Real-world data is generally consistent with clinical trial results, confirming the efficacy and safety of these biologics.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2023)

Add to Collection

Article Dermatology

Long-term use of fumaric acid esters for the treatment of psoriasis in daily practice

Christian Termeer, Uwe Reinhold, Thomas Dirschka, Ralph von Kiedrowski, Hjalmar Kurzen

Summary: This study retrospectively analyzed 200 psoriatic patients treated with FAE, showing that long-term use of FAE can improve symptoms of psoriasis with high safety. FAE therapy can be considered as a long-term, first-line treatment for moderate-to-severe plaque psoriasis.

JOURNAL OF DERMATOLOGICAL TREATMENT (2021)

Add to Collection

Article Oncology

Clinical determinants of long-term survival in metastatic uveal melanoma

Elias A. T. Koch, Anne Petzold, Anja Wessely, Edgar Dippel, Michael Erdmann, Lucie Heinzerling, Bettina Hohberger, Harald Knorr, Ulrike Leiter, Friedegund Meier, Peter Mohr, Farnaz Rahimi, Beatrice Schell, Max Schlaak, Patrick Terheyden, Beatrice Schuler-Thurner, Selma Ugurel, Jochen Utikal, Julio Vera, Michael Weichenthal, Fabian Ziller, Carola Berking, Markus Heppt

Summary: The study identified that a good response to immune checkpoint blockade, radiation therapy, or liver-directed treatments were associated with prolonged overall survival. Conversely, a poor ECOG performance status and elevated serum LDH were linked to a poorer overall survival. Long-term survivors often had more organs affected by metastasis, while patients with liver metastases only were more common among short-term survivors.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection

Article Dermatology

A long-term, prospective, observational cohort study of the safety and effectiveness of etanercept for the treatment of patients with paediatric psoriasis in a naturalistic setting

Yun Gu, Emma Brinkley, Joan Largent, Rachel E. Sobel, Sara Colli, Diamant Thaci, Marieke Seyger, Zsuzsanna Szalai, Jean-Philippe Lacour, Mona Stahle

Summary: The PURPOSE study examined the long-term safety and effectiveness of etanercept in paediatric psoriasis patients. The study found that etanercept is safe and effective in treating moderate to severe plaque psoriasis in children.

EUROPEAN JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Article Dermatology

Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis

M. Gooderham, A. Pinter, L. K. Ferris, R. B. Warren, T. Zhan, J. Zeng, A. M. Soliman, C. Kaufmann, B. Kaplan, H. Photowala, B. Strober

Summary: This study analyzed the efficacy and improvement in quality of life in patients with moderate-to-severe plaque psoriasis treated with Risankizumab. The results showed that a higher proportion of patients in the Risankizumab group achieved absolute PASI thresholds compared to the ustekinumab group, and achieved them in a shorter time. Among patients treated with long-term Risankizumab, over 90% achieved PASI <= 3, and over 80% achieved DLQI 0/1. Patients with low absolute PASI scores also had low mean absolute DLQI scores throughout the 172 weeks of continuous Risankizumab treatment.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Article Dermatology

Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide

M. E. van Muijen, L. S. van der Schoot, J. M. P. A. van den Reek, E. M. G. J. de Jong

Summary: The dose reduction of biologics for psoriasis is a common practice among psoriasis experts globally, with variations in strategies and criteria among dermatologists. Motivations for applying dose reduction include cost savings, while barriers include lack of scientific evidence and guidelines, and uncertainty about the effects and risks of dose reduction. Further research and development of guidelines are needed to accumulate evidence and ensure the feasibility and safety of dose reduction strategies.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2022)

Add to Collection

Article Dermatology

Predictors of surgical treatment burden, outcomes, and overall survival in older adults with basal cell carcinoma: Results from the prospective, multicenter BATOA cohort

Marieke E. C. van Winden, Ewald M. Bronkhorst, M. Birgitte Visch, Gertruud A. M. Krekels, Simone van der Geer, Godelieve W. J. A. Damen, Avital Amir, Katja K. H. Aben, Marie-Jeanne J. P. Gerritsen, Peter C. M. van de Kerkhof, Elke M. G. J. de Jong, Satish F. K. Lubeek

Summary: This study evaluated predictors of treatment burden, outcomes, and survival in older patients with BCC aged 70 years and above in the head and neck area. Results showed that factors associated with higher treatment burden included iADL dependency, female sex, complications, larger tumor diameter, and polypharmacy. Early intervention for robust patients or those experiencing symptoms was beneficial based on the data.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Add to Collection

Meeting Abstract Rheumatology

COMPARING METHOTREXATE MONOTHERAPY WITH METHOTREXATE PLUS LEFLUNOMIDE COMBINATION THERAPY IN PSORIATIC ARTHRITIS: A RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL (COMPLETE-PSA)

M. L. M. Mulder, J. E. Vriezekolk, T. Van Hal, L. Nieboer, N. Den Broeder, E. M. G. J. De Jong, A. Den Broeder, F. Van den Hoogen, P. Helliwell, M. Wenink

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Letter Dermatology

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab

Lara S. van Der Schoot, Selma Atalay, Marisol E. Otero, Wietske Kievit, Juul M. P. A. van den Reek, Elke M. G. J. de Jong

BRITISH JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID)

Kevin V. Kwee, Jean-Luc Murk, Qiqi Yin, M. Birgitte Visch, Linda Davidson, Elke M. G. J. de Jong, Juul M. P. A. van den Reek, Milan Tjioe

Summary: The study aimed to estimate the prevalence of SARS-CoV-2 infection in psoriasis patients, compare infection rates among different treatment groups, and describe severe COVID-19 cases. The findings suggest that the risk of SARS-CoV-2 infection is not increased for psoriasis patients using biologics or non-biologic systemic therapy compared to other treatments.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Article Dermatology

Development of a New Referral Tool to Identify Psoriasis Patients with Concomitant Psoriatic Arthritis: Results of the Prospective DAPPER Cohort

Tamara W. Van Hal, Michelle L. M. Mulder, Mark H. Wenink, Frank H. J. Van Den Hoogen, Jake S. F. Maurits, Marcel C. Pasch, Juul M. P. A. Van Den Reek, Elke M. G. J. De Jong

Summary: In this study, researchers used data from the DAPPER study to identify predictive variables for concomitant psoriatic arthritis and created a referral tool based on these variables, with an area under the curve of 0.82. This referral tool could assist dermatologists in identifying psoriasis patients with concomitant psoriatic arthritis.

ACTA DERMATO-VENEREOLOGICA (2023)

Add to Collection

Article Dermatology

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice

L. S. van der Schoot, J. J. Janssen, M. T. Bastiaens, A. de Boer-Brand, C. Christiaansen-Smit, D. N. H. Enomoto, R. Hovingh, R. A. Tupker, M. M. B. Seyger, L. M. Verhoef, J. M. P. A. van den Reek, E. M. G. J. de Jong

Summary: Implementation of protocolized biologic dose reduction can increase patient uptake of treatment, with additional staff support, extra consultation time, education for healthcare providers and patients, and effective tools such as a feasible protocol leading to more patients on biologic dose reduction.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Letter Dermatology

Identification of children at risk for the development of severe paediatric plaque psoriasis: Findings from the prospective observational long-term Child-CAPTURE registry

Inge M. G. J. Bronckers, Elke M. G. J. de Jong, Celia A. J. Michielsens, Hans M. M. Groenewoud, Peter C. M. van de Kerkhof, Marieke M. B. Seyger

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Add to Collection

Article Dermatology

Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three-year follow-up data of a single-blind randomized controlled trial

Astrid M. van Huizen, Gayle E. van der Kraaij, Celine I. Busard, Wouter Ouwerkerk, Juul M. P. A. van den Reek, Stef P. Menting, Errol P. Prens, Theo Rispens, Annick de Vries, Elke M. G. J. de Jong, Jo Lambert, Martijn B. A. van Doorn, Phyllis I. Spuls

Summary: This study compared the long-term effectiveness and safety of the combination of methotrexate and adalimumab with adalimumab monotherapy in patients with moderate to severe plaque type psoriasis. The results showed a trend towards longer drug survival in the combination therapy group, but no significant difference was found compared to the monotherapy group. Similar conclusions were drawn regarding the efficacy, safety, pharmacokinetics, and immunogenicity of the drugs. Overall, combination therapy may have a better effect in individual patients.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Add to Collection

Editorial Material Dermatology

How to define a super-responder' to biologics in psoriasis studies

Sarah E. Thomas, Juul M. P. A. Van den Reek, Marieke M. B. Seyger, Elke M. G. J. de Jong

Summary: In this study, the researchers aimed to synthesize the various definitions of super-responders in psoriasis literature and evaluate their impact on the composition of the super-responder group.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Editorial Material Dermatology

Should we prefer biologics over nonbiological agents in psoriasis?

Sarah E. Thomas, Juul M. P. A. Van den Reek

BRITISH JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Article Dermatology

Patients' perspectives towards biologic dose reduction in psoriasis: a qualitative study

L. S. van der Schoot, L. M. Verhoef, I. van Ee, F. P. A. H. van Oort, A. H. Pieterse, M. M. B. Seyger, E. M. G. J. de Jong, J. M. P. A. van den Reek

Summary: This study aimed to explore patients' perspectives towards dose reduction of biologics for psoriasis. Patients perceived benefits of dose reduction including minimizing medication use, lowering risks of adverse effects, and lowering healthcare costs. However, they also expressed concerns about the potential loss of disease control. Addressing patients' concerns, fulfilling information needs, providing the possibility of resuming standard dose, and involving patients in decision-making are important when considering biologic dose reduction.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2023)

Add to Collection

Meeting Abstract Dermatology

Discovery of arthritis in psoriatic patients for early rheumatological referral: the DAPPER study

T. van Hal, M. Mulder, M. Wenink, J. van den Reek, E. de Jong

BRITISH JOURNAL OF DERMATOLOGY (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.